Top Page
Alphamab Oncology
(9966)
Alphamab Oncology (9966) vs. iShares MSCI Hong Kong ETF (EWH)
Alphamab Oncology Business Overview & Revenue Model
Alphamab Oncology Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 785.96M | 640.08M | 218.77M | 166.84M | 146.02M | 0.00 |
| Gross Profit | 725.19M | 579.77M | 163.54M | 122.64M | 142.99M | 0.00 |
| EBITDA | 243.26M | 156.79M | -129.30M | -391.83M | -358.13M | -390.47M |
| Net Income | 232.81M | 166.34M | -210.59M | -325.72M | -412.42M | -427.77M |
Balance Sheet | ||||||
| Total Assets | 2.36B | 2.24B | 2.14B | 2.12B | 2.71B | 2.64B |
| Cash, Cash Equivalents and Short-Term Investments | 1.64B | 1.57B | 1.41B | 1.35B | 1.99B | 2.06B |
| Total Debt | 273.48M | 185.96M | 257.08M | 345.39M | 637.27M | 222.81M |
| Total Liabilities | 503.95M | 409.87M | 465.00M | 559.86M | 834.80M | 366.44M |
| Stockholders Equity | 1.85B | 1.83B | 1.67B | 1.56B | 1.87B | 2.27B |
Cash Flow | ||||||
| Free Cash Flow | 217.62M | 190.56M | -239.02M | -429.96M | -478.72M | -438.00M |
| Operating Cash Flow | 256.48M | 212.34M | -202.84M | -300.31M | -320.60M | -347.18M |
| Investing Cash Flow | -496.65M | -92.93M | -18.11M | 850.76M | 574.26M | -1.52B |
| Financing Cash Flow | -75.05M | -98.96M | 218.07M | -310.90M | 363.90M | 186.58M |
Alphamab Oncology Technical Analysis
Alphamab Oncology Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | HK$9.86B | 51.80 | 6.73% | ― | 23.37% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$10.93B | 42.78 | 13.34% | ― | 206.58% | ― | |
51 Neutral | HK$9.23B | -32.42 | -12.74% | ― | -76.58% | -4.90% | |
51 Neutral | HK$11.29B | 17.32 | 35.80% | ― | 59.70% | 239.97% | |
45 Neutral | HK$2.15B | ― | -55.33% | ― | -100.00% | 30.68% | |
40 Underperform | HK$10.71B | -51.15 | -21.42% | ― | 240.05% | -140.09% |
Alphamab Oncology Corporate Events
Alphamab Oncology announced a decision to repurchase up to HK$30 million worth of its own shares from the open market, as authorized by a mandate approved at their annual general meeting. This move is intended to reflect the company’s confidence in its business prospects and to potentially enhance shareholder value, while being financed through existing cash reserves. The repurchase plan is subject to market conditions and regulatory compliance, with no guarantee on the timing or quantity of shares to be repurchased.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced that its drug JSKN003 has received Fast Track Designation from the U.S. FDA for treating platinum-resistant recurrent epithelial ovarian cancer and related conditions. This designation highlights the promising clinical data and potential of JSKN003, which has also received multiple designations for other cancers, indicating strong international regulatory confidence. The development of JSKN003 addresses a significant unmet need in ovarian cancer treatment, offering improved efficacy over existing therapies and potentially expediting its clinical development and regulatory review.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced that its drug JSKN003 has received Fast Track Designation from the U.S. FDA for treating platinum-resistant recurrent epithelial ovarian cancer and related conditions. This designation highlights the promising clinical data and potential of JSKN003, which has also received multiple designations for other cancers, indicating strong international regulatory confidence. The development of JSKN003 addresses a significant unmet need in ovarian cancer treatment, offering improved efficacy over existing therapies and potentially expediting its clinical development and regulatory review.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has announced the grant of 1,990,176 award shares under its Restricted Share Award Scheme to three eligible participants, including two executive directors and an employee. This move is part of the company’s strategy to reward and incentivize key personnel, aligning with its remuneration policy and long-term growth objectives. The shares will vest in batches over a period of up to ten years, reflecting the company’s commitment to retaining talent and enhancing its competitive positioning in the oncology sector.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced that its drug JSKN003, co-developed with Shanghai JMT-Bio Technology, has been granted breakthrough therapy designation by the CDE for treating HER2+ advanced colorectal cancer (CRC) in patients who have failed prior treatments. This designation highlights the significant unmet clinical need in China, where CRC is highly prevalent, and no HER2-targeted therapies are currently approved. Preliminary results from clinical trials show JSKN003’s notable efficacy and favorable safety profile, potentially positioning it as a promising treatment option for HER2-overexpressing CRC patients.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has announced promising research updates for its drug JSKN003, presented at the ESMO Congress 2025. The drug showed significant efficacy and a manageable safety profile in treating patients with primary platinum-refractory ovarian cancer (OC) and HER2+ metastatic colorectal cancer (CRC). The results indicate a potential new treatment option for these patient groups, which have limited existing therapies. The company is also progressing with a phase III study comparing JSKN003 to standard chemotherapy in patients with platinum-resistant ovarian cancer (PROC), which could further establish its position in the oncology market.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced promising interim results from a Phase III clinical trial of KN026, a next-generation HER2-targeted therapy, in combination with chemotherapy for HER2+ gastric cancer patients. The trial demonstrated significant improvements in progression-free survival and overall survival compared to chemotherapy alone, with a manageable safety profile, positioning KN026 as a potential new treatment option for patients who have progressed on trastuzumab-based therapy.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has released additional information regarding its 2024 Annual Report, focusing on the utilization of treasury shares, proceeds from its Global Offering and Top-up Placing, and its Post-IPO Share Award Scheme. The company has yet to decide on the use of its treasury shares, while significant proceeds remain allocated for the development and commercialization of its key drug candidates KN046 and KN026. Additionally, funds from the Top-up Placing are primarily directed towards clinical trials and development of other drug candidates. The announcement clarifies that the Post-IPO Share Award Scheme does not require further disclosure under the Listing Rules, and the new information does not alter the previously disclosed details in the annual report.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has announced a voluntary on-market share repurchase plan, with the board resolving to buy back shares worth up to HK$20 million. The decision reflects the company’s confidence in its business prospects and aims to enhance shareholder value, though the execution of the repurchase will depend on market conditions.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced a non-compliance incident involving Mr. Cho, a non-executive director, whose spouse sold shares during a black-out period without prior notification. The company is taking steps to prevent future incidents by enhancing compliance training and awareness among its directors and staff.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced that its new drug application for KN026, a bispecific antibody for HER2+ gastric cancer, has been accepted by China’s National Medical Products Administration. This marks a significant advancement as KN026 is the first anti-HER2 therapy in China to show positive results for second-line treatment of gastric cancer, potentially enhancing the company’s market position and offering new hope for patients who have exhausted other treatment options.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced its interim results for the first half of 2025, reporting a significant increase in revenue and a return to profitability compared to the same period in 2024. The company achieved several milestones in its clinical trials, including the publication of results for phase II studies and the initiation of phase III trials for its promising cancer treatments. These advancements are expected to strengthen Alphamab’s position in the oncology market and potentially offer new treatment options for patients with HER2-positive and other types of cancer.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has announced a supplemental agreement regarding a connected transaction with Suzhou Alphamab for technology development. The agreement outlines a payment structure where Jiangsu Alphamab will make an upfront payment followed by milestone payments linked to specific project deliverables. This collaboration is expected to enhance Alphamab’s capabilities in process development and validation, potentially strengthening its position in the oncology sector.
Alphamab Oncology announced a positive profit alert, expecting a profit of not less than RMB20.0 million for the first half of 2025, reversing a loss of approximately RMB44.9 million in the same period of 2024. This turnaround is attributed to milestone revenue from three licensed collaborations and sales revenue from a commercialized product, indicating a significant improvement in the company’s financial performance and market positioning.
Alphamab Oncology has announced that its board of directors will meet on August 28, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial health and operational progress, impacting stakeholders’ expectations and the company’s market positioning.
Alphamab Oncology has announced a technology development collaboration with Suzhou Alphamab, a connected transaction under the Hong Kong Stock Exchange rules. This agreement involves Suzhou Alphamab providing technology development services for Alphamab’s bispecific antibody-drug conjugate candidate, including developing production processes and preparing samples for regulatory filings. The partnership is valued at RMB10,240,000 and is expected to enhance Alphamab’s capabilities in bringing new cancer treatments to market, potentially strengthening its position in the biopharmaceutical industry.